Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Note: If the price history is too short, we do not calculate current Cyclically Adjusted PB Ratio for this stock. All the historical data is shown as the company's primary share's data instead.
Shiller PE for Stocks: The True Measure of Stock Valuation
Boston Scientific (CHIX:BSXd) Cyclically Adjusted PB Ratio Explanation
Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.
Boston Scientific Cyclically Adjusted PB Ratio Related Terms
Boston Scientific Cyclically Adjusted PB Ratio Historical Data
* Premium members only.
The historical data trend for Boston Scientific's Cyclically Adjusted PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Boston Scientific Cyclically Adjusted PB Ratio Chart
CHIX:BSXD vs EW, GEHC, MDT: Cyclically Adjusted PB Ratio Comparison
For the Medical Devices subindustry, Boston Scientific's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Boston Scientific Cyclically Adjusted PB Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Boston Scientific's Cyclically Adjusted PB Ratio distribution charts can be found below:
* The bar in red indicates where Boston Scientific's Cyclically Adjusted PB Ratio falls into.
Boston Scientific Cyclically Adjusted PB Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Is Boston Scientific (CHIX:BSXD) Overvalued in 2026?
Based on GuruFocus' analysis, Boston Scientific stock appears to be undervalued.
The current stock price of €37.64 is trading 59% below its estimated GF Value™ of €91.85.
GuruFocus considers Boston Scientific to be Significantly Undervalued.
Key valuation signals for CHIX:BSXD:
Cyclically Adjusted PB Ratio:
GF Value™: €91.85 vs. price of €37.64 (59% below fair value)
No single metric tells the full story. See the CHIX:BSXD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.
67GF Score
Get the complete analysis for CHIX:BSXD
Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:BSXD has been successfully added to your 
